Search research articles
Contact Us
Filters
Showing results (81-90 of 252) with videos related to
Page
of 26
Sort By:
Hemasphere
|
February 24, 2021
Hematologic Rescue of CAR T-cell-mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient
Philipp Gödel, Noëlle Sieg, Jan-Michel Heger, et al.
BMC Cancer
|
November 11, 2020
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
Anna Sureda, Marc André, Peter Borchmann, et al.
Blood Advances
|
March 5, 2026
Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma
Marie Anne-Catherine Neumann, Jessica Schneider, Max Szameitat, et al.
Blood
|
August 2, 2018
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Lena Schröder, et al.
Leukemia
|
August 23, 2018
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
Sven Borchmann, Horst Müller, Heinz Haverkamp, et al.
Leukemia & Lymphoma
|
April 27, 2013
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant
Sally Arai, Michelle Fanale, Sven DeVos, et al.
Leukemia
|
October 23, 2019
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
Blood
|
October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Blood
|
August 11, 2011
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
Dennis A Eichenauer, Michael Fuchs, Annette Pluetschow, et al.
International Journal of Cancer
|
September 2, 2024
Humoral immune response as an indicator for protection against Covid-19 after anti-SARS-COV2-booster vaccination in hematological and oncological patients
Dieter Mainka, Nathalie Bauer, Lutz Dietze, et al.
Page
of 26
Search research articles
Search
Showing results (81-90 of 252) with videos related to
Sort By:
Page
of 26
Hemasphere
|
February 24, 2021
Hematologic Rescue of CAR T-cell-mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient
Philipp Gödel, Noëlle Sieg, Jan-Michel Heger, et al.
BMC Cancer
|
November 11, 2020
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
Anna Sureda, Marc André, Peter Borchmann, et al.
Blood Advances
|
March 5, 2026
Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma
Marie Anne-Catherine Neumann, Jessica Schneider, Max Szameitat, et al.
Blood
|
August 2, 2018
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Lena Schröder, et al.
Leukemia
|
August 23, 2018
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
Sven Borchmann, Horst Müller, Heinz Haverkamp, et al.
Leukemia & Lymphoma
|
April 27, 2013
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant
Sally Arai, Michelle Fanale, Sven DeVos, et al.
Leukemia
|
October 23, 2019
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
Blood
|
October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Blood
|
August 11, 2011
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
Dennis A Eichenauer, Michael Fuchs, Annette Pluetschow, et al.
International Journal of Cancer
|
September 2, 2024
Humoral immune response as an indicator for protection against Covid-19 after anti-SARS-COV2-booster vaccination in hematological and oncological patients
Dieter Mainka, Nathalie Bauer, Lutz Dietze, et al.
Page
of 26